Detalles de la búsqueda
1.
3-year invasive disease-free survival with chemotherapy de-escalation using an 18F-FDG-PET-based, pathological complete response-adapted strategy in HER2-positive early breast cancer (PHERGain): a randomised, open-label, phase 2 trial.
Lancet
; 403(10437): 1649-1659, 2024 Apr 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-38582092
2.
Correlation between trophoblast cell-surface antigen-2 (Trop-2) expression and pathological complete response in patients with HER2-positive early breast cancer treated with neoadjuvant docetaxel, carboplatin, trastuzumab, and pertuzumab.
Breast Cancer Res Treat
; 205(3): 589-598, 2024 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-38456970
3.
Clinicopathological and molecular predictors of [18F]FDG-PET disease detection in HER2-positive early breast cancer: RESPONSE, a substudy of the randomized PHERGain trial.
Eur J Nucl Med Mol Imaging
; 2024 Apr 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-38587643
4.
Palbociclib with Fulvestrant or Letrozole in Endocrine-Sensitive Patients with HR-Positive/HER2-Negative Advanced Breast Cancer: A Detailed Safety Analysis of the Randomized PARSIFAL Trial.
Oncologist
; 28(1): 23-32, 2023 01 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-36239405
5.
Trastuzumab and pertuzumab without chemotherapy in early-stage HER2+ breast cancer: a plain language summary of the PHERGain study.
Future Oncol
; 18(33): 3677-3688, 2022 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-36300423
6.
Chemotherapy de-escalation using an 18F-FDG-PET-based pathological response-adapted strategy in patients with HER2-positive early breast cancer (PHERGain): a multicentre, randomised, open-label, non-comparative, phase 2 trial.
Lancet Oncol
; 22(6): 858-871, 2021 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-34019819
7.
Agreement between the results of meta-analyses from case reports and from clinical studies regarding the efficacy of laronidase therapy in patients with mucopolysaccharidosis type I who initiated enzyme replacement therapy in adult age: An example of case reports meta-analyses as an useful tool for evidence-based medicine in rare diseases.
Mol Genet Metab
; 123(2): 69-75, 2018 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-29336994
8.
Retifanlimab in Advanced Penile Squamous Cell Carcinoma: The Phase 2 ORPHEUS Study.
Eur Urol Oncol
; 2024 May 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-38749903
9.
Optimal [18F]FDG PET/CT Cutoff for Pathologic Complete Response in HER2-Positive Early Breast Cancer Patients Treated with Neoadjuvant Trastuzumab and Pertuzumab in the PHERGain Trial.
J Nucl Med
; 65(5): 708-713, 2024 May 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-38575192
10.
Preventing alpelisib-related hyperglycaemia in HR+/HER2-/PIK3CA-mutated advanced breast cancer using metformin (METALLICA): a multicentre, open-label, single-arm, phase 2 trial.
EClinicalMedicine
; 71: 102520, 2024 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-38638399
11.
A single-arm study design with non-inferiority and superiority time-to-event endpoints: a tool for proof-of-concept and de-intensification strategies in breast cancer.
Front Oncol
; 13: 1048242, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37496662
12.
Trastuzumab deruxtecan in patients with central nervous system involvement from HER2-positive breast cancer: The DEBBRAH trial.
Neuro Oncol
; 25(1): 157-166, 2023 01 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-35639825
13.
Palbociclib Rechallenge for Hormone Receptor-Positive/HER-Negative Advanced Breast Cancer: Findings from the Phase II BioPER Trial.
Clin Cancer Res
; 29(1): 67-80, 2023 01 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-36165912
14.
Pembrolizumab in combination with tocilizumab in high-risk hospitalized patients with COVID-19 (COPERNICO): A randomized proof-of-concept phase II study.
Int J Infect Dis
; 123: 97-103, 2022 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-35987472
15.
Radium-223 for patients with metastatic castration-resistant prostate cancer with asymptomatic bone metastases progressing on first-line abiraterone acetate or enzalutamide: A single-arm phase II trial.
Eur J Cancer
; 173: 317-326, 2022 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-35981452
16.
Predictive Role of Leptin Receptor (Ob-R) Overexpression in Patients with Early Breast Cancer Receiving Neoadjuvant Systemic Treatment.
Cancers (Basel)
; 13(13)2021 Jun 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-34210055
17.
The Impact of Excluding Nonrandomized Studies From Systematic Reviews in Rare Diseases: "The Example of Meta-Analyses Evaluating the Efficacy and Safety of Enzyme Replacement Therapy in Patients With Mucopolysaccharidosis".
Front Mol Biosci
; 8: 690615, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-34239895
18.
Surrogate endpoints for early-stage breast cancer: a review of the state of the art, controversies, and future prospects.
Ther Adv Med Oncol
; 13: 17588359211059587, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-34868353
19.
Pembrolizumab plus eribulin in hormone-receptor-positive, HER2-negative, locally recurrent or metastatic breast cancer (KELLY): An open-label, multicentre, single-arm, phase â ¡ trial.
Eur J Cancer
; 148: 382-394, 2021 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-33794440
20.
Fulvestrant-Palbociclib vs Letrozole-Palbociclib as Initial Therapy for Endocrine-Sensitive, Hormone Receptor-Positive, ERBB2-Negative Advanced Breast Cancer: A Randomized Clinical Trial.
JAMA Oncol
; 7(12): 1791-1799, 2021 12 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34617955